课题基金 / 基金详情

Anaerobic Bacteria as Therapeutic Agents for Metastatic

Anaerobic Bacteria as Therapeutic Agents for Metastatic
厌氧细菌作为转移性治疗剂
批准号:
7025161
负责人:
Savio L Woo
金额:
$16.1万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-02-01 至 2008-01-31

项目摘要

项目成果

Savio L Woo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): As they grow in volume many tumors, including pancreatic and colon cancers, construct poorly vascularized and oxygen-deficient (hypoxic) areas that restrict the access by therapeutic agents and limit the efficacy of currently used anti-cancer modalities. However, the presence of hypoxia also offers the potential for anaerobic bacterial colonization that can lead to tumor destruction. One such anerobic bacterium is Clostridium perfringens (Cp), which contains a major toxin gene that encodes phospholipase C (plc). A plc-deleted strain of Cp (Cp/plc-) has been constructed in our laboratory and shown, after intravenous administration, to colonize and induce massive necrosis in solid tumors in mice. Unfortunately Cp/plc- retains some tolerance to oxygen that enables it to grow in normal tissues at a much reduced rate, and tumor-bearing mice treated with Cp/plc- at the effective doses also exhibited systemic toxicity. We hypothesize that Cp/plc- can be genetically modified to reduce substantially its oxygen tolerance, thereby creating sub-strains that will lead to tumor destruction without toxicity to normal tissues. We propose to delete the superoxide dismutase (sod) gene in a luciferase-expressing strain of Cp/plc-/LUC+ (Cp/plc-/sod-/LUC+). Immune- competent mice with pre-established syngeneic colorectal and pancreatic cancers in the liver will be treated by intravenous administration of Cp/plc-/sod-. Dose response curve and long-term survival at the maximal tolerated dose will be determined. Bacterial biodistribution and intratumoral growth will be determined as a function of time by repeated non-invasive whole-body imaging using luciferrin. Tumor responses in the treated animals will be evaluated by histological examination. Toxicity endpoints will include CBC, blood chemistries, serum proinflammatory cytokine levels and history of major organs. If necessary, additional oxygen tolerance genes can be deleted from Cp/plc-/sod- to further reduce toxicity. We hypothesize that these oxygen-intolerant mutant bacterial sub-strains can be safely applied in tumor-bearing animals, which will selectively localize to, germinate and grow in, and destroy tumors in hypoxic regions. Application of anaerobic bacterial-based vectors is a promising strategy for the development of an effective therapeutic agent that can be administered systemically to treat disseminated solid tumors with hypoxia, and may lead to clinical translational studies in patients with metastatic colorectal and/or pancreatic cancers in the future.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anaerobic Bacteria as Oncopathic Agents for Pancreatic Cancer
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
Phase I Clinical Translation Trial of Oncolytic rVSV-F Virotherapy for HCC
海外基金